BACKGROUND Rotaviruses are the most important cause of severe acute gastroenteritis worldwide in children <5 years of age. The human, G1P rotavirus vaccine Rotarix™ significantly reduced severe rotavirus gastroenteritis episodes in a Phase III clinical trial conducted in infants in South Africa and Malawi. This paper examines rotavirus vaccine efficacy… (More)
Subsequent to publication of this paper errors in Table 5 (solicited local and systemic adverse events…) have come to light. Below is the revised table.